---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-129750"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:39:34.510247+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout

## Summary
- Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.
- Earnout tied to Extract Labs revenue targets: $3.5M-$4.6M per 12-month period for two years.
- Acquisition expected to close in Q1 2025, subject to customary conditions.
- CV Sciences plans to in-source +PlusCBD production, citing cost savings and supply chain control.
- Extract Labs described as stand-alone profitable, GMP-certified, and FDA-registered.

## SEC filing metadata
- accession: 0000950170-24-129750
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000095017024129750/0000950170-24-129750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000095017024129750/cvsi-20241115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-129750
- JSON: https://secwatch.observer/filing/0000950170-24-129750.json
- Plain text: https://secwatch.observer/filing/0000950170-24-129750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.